Nanexa AB (NANEXA) AI Stock Analysis

• Market Cap: €354.61M
• Dividend Yield: N/A
• Average Volume (3M): 408.93K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.39
• Revenue Growth: -38.56%
• EPS Growth: 69.37%
• Country: SE
• Employees: 13
• Sector: Healthcare
• Sector Strength: 45
• Industry: Drug Manufacturers - Specialty & Generic
• EPS (TTM): -0.06
• Shares Outstanding: 156,907,750
• 10 Day Avg. Volume: 305,840
• 30 Day Avg. Volume: 408,926
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: €2.51
• Price Target Upside: 13.28% Upside
• Rating Consensus: Hold
• Number of Analyst Covering: 0

• Rating: 46 Neutral
• Price Target: kr2.00 ▼(-9.91% Downside)

The overall stock score is primarily impacted by significant financial challenges, including declining revenues and persistent losses. Technical analysis provides some positive signals, but valuation metrics remain weak due to negative earnings. The absence of earnings call data and corporate events limits further insights.

Nanexa AB Business Overview & Revenue Model

Company Description

Nanexa AB (publ) operates as a nanotechnology drug delivery company. It operates PharmaShell, a nanobased drug delivery platform that is an atomic layer deposition. The company also develops NEX-18, which drives the development of a PharmaShell that targets myelodysplastic Syndrome and Acute Myeloid Leukemia. Nanexa AB (publ) was founded in 2007 and is based in Uppsala, Sweden.

How the Company Makes Money

Nanexa AB primarily generates revenue through partnerships and collaborations with pharmaceutical companies that seek to leverage its PharmaShell technology for their drug development projects. These partnerships often involve licensing agreements where Nanexa provides its proprietary coating technology in exchange for milestone payments, licensing fees, and royalties based on the commercial success of the partnered drugs. Additionally, Nanexa may engage in research and development contracts where it offers its expertise in drug formulation and delivery solutions, further contributing to its revenue streams. The company’s growth and revenue are significantly influenced by its ability to establish and maintain strategic partnerships within the pharmaceutical industry.

Nanexa AB Financial Statement Overview

Summary

Nanexa AB is facing significant financial challenges across all key financial statements. The company struggles with profitability due to negative net profit margins and high operational costs. Despite a strong equity position, rising debt levels and negative cash flow highlight financial instability.

Income Statement

Nanexa AB shows significant revenue volatility with a decline in total revenue from 2023 to 2024. The net profit margin is negative, indicating persistent losses. Gross profit margin is positive, yet the EBIT and EBITDA margins are severely negative, reflecting high operational costs relative to revenue. Overall, the company struggles with profitability and growth consistency.

Balance Sheet

Nanexa AB maintains a relatively strong equity position with an equity ratio of 71.3% in the latest TTM. However, the debt-to-equity ratio increased compared to previous periods, indicating growing leverage. The return on equity is negative, highlighting unprofitable operations despite a substantial equity base. Financial stability is supported by a strong equity position but is offset by rising debt levels.

Cash Flow

The company faces negative free cash flow, consistent with its operating losses. The operating cash flow to net income ratio is less favorable, indicating cash burn issues. Free cash flow growth remains negative, suggesting ongoing liquidity challenges despite occasional financing inflows. Overall, cash flow management appears weak with a need for improving operational efficiency.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	16.53M	24.36M	29.33M	2.86M	2.37M	2.37M
Gross Profit	38.40M	46.69M	59.16M	3.40M	4.31M	20.86M
EBITDA	-17.08M	-18.99M	-70.79M	-53.86M	-32.92M	-16.28M
Net Income	-30.95M	-24.91M	-76.40M	-58.57M	-36.00M	-21.74M
Balance Sheet
Total Assets	126.55M	91.82M	132.26M	170.19M	165.00M	53.69M
Cash, Cash Equivalents and Short-Term Investments	40.26M	10.29M	65.17M	81.18M	105.66M	12.69M
Total Debt	21.57M	3.71M	4.03M	6.27M	3.83M	3.89M
Total Liabilities	36.63M	20.90M	36.43M	61.10M	13.70M	10.34M
Stockholders Equity	89.92M	70.92M	95.83M	109.10M	151.29M	43.35M
Cash Flow
Free Cash Flow	-54.98M	-54.55M	-76.91M	-43.29M	-50.92M	-37.63M
Operating Cash Flow	-28.07M	-26.43M	-42.66M	-7.87M	-25.13M	-16.83M
Investing Cash Flow	-26.91M	-28.12M	-34.25M	-35.42M	-25.79M	-20.80M
Financing Cash Flow	53.93M	-327.00K	60.89M	18.81M	143.89M	38.94M

Nanexa AB Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 2.22
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:NANEXA, the sentiment is Neutral. The current price of 2.22 is below the 20-day moving average (MA) of 2.26, below the 50-day MA of 2.24, and above the 200-day MA of 1.91, indicating a neutral trend. The MACD of 0.02 indicates Positive momentum. The RSI at 48.73 is Neutral, neither overbought nor oversold. The STOCH value of 26.76 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for SE:NANEXA.

Nanexa AB Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
ALZCUR	47 Neutral	326.36M	-7.20	0.00%	―	0.00%	22.73%
NANEXA	46 Neutral	€354.61M	―	-34.87%	―	-38.56%	69.37%
KLAR	41 Neutral	143.16M	-1.85	0.00%	―	1523.75%	20.82%
ENZY	41 Neutral	563.15M	-10.22	-30.15%	―	11.87%	26.50%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%